About Brigatinib API

Mechanism of Action

Brigatinib is a type of cancer drug known as an ALK (anaplastic lymphoma kinase) inhibitor. It works by blocking the activity of ALK, a protein that is often over-expressed in certain types of cancer cells, such as non-small cell lung cancer (NSCLC).

The over-expression of ALK leads to uncontrolled cell growth and division, which is a hallmark of cancer. Brigatinib interferes with the activity of ALK by binding to the ALK protein and preventing it from interacting with other proteins that are essential for cell survival and proliferation.

By inhibiting the activity of ALK, brigatinib can help to slow the growth and spread of cancer cells. This can lead to a reduction in the size of tumors and an improvement in overall cancer symptoms.

It is important to note that the mechanism of action of brigatinib may vary depending on the type and stage of cancer being treated. The use of brigatinib should be guided by the recommendations of a healthcare provider who is familiar with the patient's medical history and current condition.

Indication

Brigatinib is a medication that is used to treat a type of cancer known as non-small cell lung cancer (NSCLC). Specifically, it is indicated for the treatment of patients with ALK (anaplastic lymphoma kinase) positive NSCLC who have progressed on or are intolerant to crizotinib.

ALK positive NSCLC is a subtype of NSCLC that is characterized by a genetic alteration in the ALK gene. This alteration leads to the over-expression of ALK, which drives the growth and spread of cancer cells.

Brigatinib works by inhibiting the activity of ALK, which helps to slow the growth and spread of cancer cells. By doing so, it can help to reduce the size of tumors and improve overall cancer symptoms.

It is important to note that the use of brigatinib should be guided by the recommendations of a healthcare provider who is familiar with the patient's medical history and current condition. The drug should only be used in patients with ALK positive NSCLC, as its safety and efficacy have not been established in other types of cancer.

Dr. Reddy’sの専門知識・技術

ハイデラバード（インド）に本社を構えるDr. Reddy’s Laboratoriesは、世界的に有名な原薬（API）供給業者です。Dr. Reddy’sのAPIビジネスは米国、ヨーロッパ、ブラジル、南米、日本、中国、韓国、その他の新興市場において製薬会社の推奨パートナーとなっています。

Dr. Reddy’sのAPIビジネスは、ステロイド、ペプチド、複合長鎖分子、高薬理活性API（HPAPI /腫瘍学薬）など、複合APIの開発・製造において、30年以上にわたり高度な技術的実績を築き上げ、成長しています。この専門知識・技術は弊社の知的財産および規制関連業務の実績と共に、一貫して規制基準を満たし、それを超える優れた価値を生み出しています。Dr. Reddyの(-) API, R&D (研究開発)、IP、規制の高度な専門知識・技能の結果です。

顧客が真っ先に市場に参入するのに重要な要素は、機敏な供給網です。弊社は全施設を効率的に、そしてコストを最適化して稼働させ、品質と安全性、また、生産性の最新基準に従うことで、そうした供給網を実現させます。オフィスと工場の結びつきを強化し、ダイナミックな市場の変化に迅速に対応しています。そうした理由から、弊社は不足を解消して突発的な供給を満たすことができるのです。